title: A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
authors.forename: Adrian
authors.initials: A
authors.lastname: Tempescul
authors.forename: Johanna
authors.initials: J
authors.lastname: Feuerbach
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Ianotto
authors.forename: Florence
authors.initials: F
authors.lastname: Dalbies
authors.forename: Veronique
authors.initials: V
authors.lastname: Marion
authors.forename: Marie-Josée
authors.initials: MJ
authors.lastname: Le Bris
authors.forename: Marc
authors.initials: M
authors.lastname: De Braekeleer
authors.forename: Christian
authors.initials: C
authors.lastname: Berthou
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D054403:Leukemia, Prolymphocytic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D008942:Mitoxantrone; D014740:Vidarabine; C024352:fludarabine